BioSpace News Archive

Included in the purchase are all applications, programs, designs, drawings, source codes, schematics, and U.S. FDA 510(k) certificates for all DRX9000™ spinal decompression devices along with four trademarks, including the “DRX®" mark.

System features Trident II Tritanium, building on Trident brand legacy, combining the reproducibility of AMagine™ additive manufactured Tritanium® In-Growth Technology with the precision of Mako Robotic-Arm Assisted Surgery[1]

Micropep Technologies, developing a non-GMO new generation of bioherbicides and biostimulants, is the third investment of the Sofinnova IB I fund dedicated to industrial biotech; Sofinnova IB I, which recently closed at €125M, is the largest European fund dedicated to sustainable transition of the chemical industry.

Authorization allows 23andMe to report on BRCA1- and BRCA2-related genetic risk for breast, ovarian and prostate cancer

PharmScript, a leading pharmacy provider to long-term care and post-acute care facilities, today announced the acquisitions of Arxcare and Vinze Pharmacare.

California-Based Health Policy Organization’s New Headquarters in China Basin Neighborhood Features Event Space

Aytu BioScience, Inc. (NASDAQ: AYTU) (the “Company”), a specialty life sciences company focused on global commercialization of novel products in the field of urology, today announced the closing of its previously announced underwritten public offering for total gross proceeds of $12,000,000, before deducting underwriting discounts, commissions and other offering expenses payable by the Company.

Commvault has announced a new partnership with MEDITECH Holdings South Africa that will allow electronic health record (EHR) specialists to expand the breadth of data management, compliance and record management solutions to its customers throughout Europe, Africa, Singapore and Australasia.

Total joint replacement (TJR) is one of the most commonly performed, elective surgical procedures in the United States, and the volume of primary and revision TJR procedures has risen continuously in recent decades, a new study presented.

Rocket enters 2018 as a public company with solid financial position following successful completion of merging with Inotek Pharmaceuticals.